GSK GlaxoSmithKline plc: Total Company Value-to-Revenue Ratio

GSK Corp (GSK) - corporate logo

GSK plc relies on stable demand for asthma treatments and vaccines, which generate a steady cash flow. The EV/Sales valuation level illustrates the current market value relative to revenue, where 2732.49 serves as the final level mark. Patent protection allows the holding to maintain premium pricing, while a balanced pipeline of HIV drugs offsets legacy legal risks.

GSK GlaxoSmithKline Company Value to Revenue (11/23/2025 - 11/20/2026)

GSK (gsk.com): analytical breakdowns and indicator data

- stock value and consensus price forecast:
- company stock capitalization data:
Fundamental company valuation:GSK plc
Brand item of GSK plc

For the pharmaceutical behemoth GSK plc (GSK), it is critical to correlate market capitalization with operating revenue while excluding the impact of debt load. An analysis of the company's EV/Sales ratio allows for an assessment of real market interest in assets, stripped of volatility and debt obligations. Amid patent risks and Zantac litigation, an upward trend in this multiple signals an increase in business value, although a sharp spike warns that the asset is overbought.